$RVMD


announced very strong Phase 3 data in second line metastatic pancreatic cancer with its drug daraxonrasib, nearly doubling overall survival compared with chemotherapy. The drug reduced the risk of death by 60%; median overall survival was 13.2 months in the daraxonrasib arm versus 6.6 months in the chemotherapy arm.
This pattern is the most bullish pattern. It doesn’t have a name, I call it soup ladle
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned